BG103729A - New derivatives of carboxylic acids, their preparation and administration for cancer treatment - Google Patents
New derivatives of carboxylic acids, their preparation and administration for cancer treatmentInfo
- Publication number
- BG103729A BG103729A BG103729A BG10372999A BG103729A BG 103729 A BG103729 A BG 103729A BG 103729 A BG103729 A BG 103729A BG 10372999 A BG10372999 A BG 10372999A BG 103729 A BG103729 A BG 103729A
- Authority
- BG
- Bulgaria
- Prior art keywords
- cancer treatment
- administration
- preparation
- carboxylic acids
- new derivatives
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 2
- 150000001735 carboxylic acids Chemical class 0.000 title 1
- 206010062767 Hypophysitis Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000004696 endometrium Anatomy 0.000 abstract 1
- 210000003038 endothelium Anatomy 0.000 abstract 1
- 210000004907 gland Anatomy 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 210000002418 meninge Anatomy 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 210000003635 pituitary gland Anatomy 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 210000001550 testis Anatomy 0.000 abstract 1
- 210000001685 thyroid gland Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/818,622 US6030975A (en) | 1997-03-14 | 1997-03-14 | Carboxylic acid derivatives, their preparation and use in treating cancer |
| PCT/US1998/004596 WO1998041206A1 (en) | 1997-03-14 | 1998-03-09 | Novel carboxylic acid derivatives, their preparation and use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG103729A true BG103729A (en) | 2000-04-28 |
Family
ID=25225984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG103729A BG103729A (en) | 1997-03-14 | 1999-09-13 | New derivatives of carboxylic acids, their preparation and administration for cancer treatment |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6030975A (de) |
| EP (1) | EP0969841A1 (de) |
| JP (1) | JP2001517220A (de) |
| KR (1) | KR20000076252A (de) |
| CN (1) | CN1251991A (de) |
| AU (2) | AU744019B2 (de) |
| BG (1) | BG103729A (de) |
| BR (1) | BR9808263A (de) |
| CA (1) | CA2283732A1 (de) |
| HR (1) | HRP980126A2 (de) |
| HU (1) | HUP0002249A3 (de) |
| ID (1) | ID24283A (de) |
| IL (1) | IL131666A0 (de) |
| NO (1) | NO994426L (de) |
| NZ (1) | NZ337557A (de) |
| PL (1) | PL335688A1 (de) |
| SK (1) | SK125299A3 (de) |
| WO (1) | WO1998041206A1 (de) |
| ZA (1) | ZA982136B (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19533023B4 (de) * | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| DE19850301A1 (de) * | 1998-10-30 | 2000-05-04 | Basf Ag | Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren |
| US7566452B1 (en) * | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
| US6545048B1 (en) | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
| HUP0204139A3 (en) * | 2000-02-16 | 2003-07-28 | Yamanouchi Pharma Co Ltd | Use of n-[6-methoxi-5-(2-methoxiphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2phenyl-etienesulfonamide for producing pharmaceutical composition using for reducing pain in an endothelin-induced disease |
| WO2002064573A1 (de) * | 2001-02-14 | 2002-08-22 | Abbott Gmbh & Co. Kg | Neue carbonsäurederivate mit alkylsubstituierten triazinen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten |
| CN1568999A (zh) * | 2003-07-14 | 2005-01-26 | 南宁枫叶药业有限公司 | 稳定的医药用河豚毒素冷冻干燥制剂 |
| US20080262006A1 (en) | 2007-02-02 | 2008-10-23 | Harbeson Scott L | Selective endothelin type-a antagonists |
| CN105130855B (zh) | 2009-12-07 | 2018-05-25 | 约翰斯霍普金斯大学 | 二酰基化的羟基胺衍生物及其用途 |
| CN102276536B (zh) * | 2011-06-10 | 2015-04-29 | 中国科学院化学研究所 | 一种光学纯的(+)-安倍生坦和光学纯的(+)-达芦生坦的制备方法 |
| CN103709106A (zh) * | 2013-12-06 | 2014-04-09 | 石家庄博策生物科技有限公司 | 一种立体选择性制备安立生坦的方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5382569A (en) * | 1991-05-16 | 1995-01-17 | Warner-Lambert Company | Endotherlin antagonists |
| CA2072395A1 (en) * | 1991-07-01 | 1993-01-02 | John T. Hunt | Bicyclic endothelin analogues |
| CA2072390A1 (en) * | 1991-07-01 | 1993-01-02 | Philip D. Stein | Endothelin analogues with alpha-amine substitution at residue 20 |
| WO1993018794A1 (en) * | 1992-03-26 | 1993-09-30 | Gensia, Inc. | In vivo peptide therapy |
| FI944905A7 (fi) * | 1992-04-22 | 1994-10-19 | Warner Lambert Co | Endoteliiniantagonistit II |
| US5550110A (en) * | 1992-04-22 | 1996-08-27 | Warner-Lambert Company | Endothelin Antagonists II |
| WO1994003483A1 (en) * | 1992-07-30 | 1994-02-17 | Chiron Corporation | Endothelin receptor-binding compounds |
| TW333456B (en) * | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| AU675870B2 (en) * | 1993-08-18 | 1997-02-20 | Msd K.K. | Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives |
| SK20396A3 (en) * | 1993-08-19 | 1997-03-05 | Warner Lambert Co | Substituted 2(5h)furanone, 2(5h)thiophenone or 2(5h)pyrrolone derivatives and pharmaceutical compositions on their base |
| DE4411225A1 (de) * | 1994-03-31 | 1995-10-05 | Basf Ag | Verwendung von Carbonsäurederivaten als Arzneimittel |
| WO1996006095A1 (en) * | 1994-08-19 | 1996-02-29 | Abbott Laboratories | Endothelin antagonists |
| WO1996011927A1 (en) * | 1994-10-12 | 1996-04-25 | Abbott Laboratories | Endothelin antagonists |
| DE19533023B4 (de) * | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| PL184060B1 (pl) * | 1995-01-27 | 2002-08-30 | Rhone Poulenc Rorer Ltd | Podstawione związki fenylowe do zastosowania jako środki antagonistyczne endoteliny |
| CA2168154A1 (en) * | 1995-02-06 | 1996-08-07 | Natesan Murugesan | Substituted biphenyl sulfonamide endothelin antagonists |
| DE19614542A1 (de) * | 1996-04-12 | 1997-10-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| DE19614533A1 (de) * | 1996-04-12 | 1997-10-16 | Basf Ag | Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung |
| DE19614534A1 (de) * | 1996-04-12 | 1997-10-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| DE19636046A1 (de) * | 1996-09-05 | 1998-03-12 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten |
-
1997
- 1997-03-14 US US08/818,622 patent/US6030975A/en not_active Expired - Lifetime
-
1998
- 1998-03-09 WO PCT/US1998/004596 patent/WO1998041206A1/en not_active Ceased
- 1998-03-09 EP EP98909067A patent/EP0969841A1/de not_active Withdrawn
- 1998-03-09 HU HU0002249A patent/HUP0002249A3/hu unknown
- 1998-03-09 SK SK1252-99A patent/SK125299A3/sk unknown
- 1998-03-09 CA CA002283732A patent/CA2283732A1/en not_active Abandoned
- 1998-03-09 IL IL13166698A patent/IL131666A0/xx unknown
- 1998-03-09 KR KR1019997008347A patent/KR20000076252A/ko not_active Withdrawn
- 1998-03-09 ID IDW991021A patent/ID24283A/id unknown
- 1998-03-09 CN CN98803904A patent/CN1251991A/zh active Pending
- 1998-03-09 PL PL98335688A patent/PL335688A1/xx unknown
- 1998-03-09 JP JP54057398A patent/JP2001517220A/ja active Pending
- 1998-03-09 NZ NZ337557A patent/NZ337557A/en unknown
- 1998-03-09 AU AU66946/98D patent/AU744019B2/en not_active Ceased
- 1998-03-09 BR BR9808263-9A patent/BR9808263A/pt not_active IP Right Cessation
- 1998-03-09 AU AU6694698A patent/AU734696B2/xx not_active Expired - Lifetime
- 1998-03-10 HR HR08/818,622A patent/HRP980126A2/hr not_active Application Discontinuation
- 1998-03-13 ZA ZA9802136A patent/ZA982136B/xx unknown
-
1999
- 1999-09-13 BG BG103729A patent/BG103729A/xx unknown
- 1999-09-13 NO NO994426A patent/NO994426L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0969841A1 (de) | 2000-01-12 |
| ZA982136B (en) | 1999-09-13 |
| JP2001517220A (ja) | 2001-10-02 |
| IL131666A0 (en) | 2001-01-28 |
| CA2283732A1 (en) | 1998-09-24 |
| CN1251991A (zh) | 2000-05-03 |
| US6030975A (en) | 2000-02-29 |
| AU744019B2 (en) | 2002-02-14 |
| NO994426D0 (no) | 1999-09-13 |
| SK125299A3 (en) | 2001-12-03 |
| KR20000076252A (ko) | 2000-12-26 |
| WO1998041206A1 (en) | 1998-09-24 |
| PL335688A1 (en) | 2000-05-08 |
| ID24283A (id) | 2000-07-13 |
| NO994426L (no) | 1999-11-12 |
| AU734696B2 (en) | 2001-06-21 |
| BR9808263A (pt) | 2000-05-16 |
| HRP980126A2 (en) | 1998-12-31 |
| NZ337557A (en) | 2001-08-31 |
| HUP0002249A2 (hu) | 2001-05-28 |
| HUP0002249A3 (en) | 2001-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG103729A (en) | New derivatives of carboxylic acids, their preparation and administration for cancer treatment | |
| IL133585A0 (en) | Soluble prodrugs of paclitaxel | |
| EP0972517A3 (de) | Anwendung von 1,2,4-benzotriazinoxiden zur Herstellung eines Arzneimittels zur Behandlung von Tumoren | |
| EA200001043A2 (ru) | Соединения для лечения женской сексуальной дисфункции | |
| GR3034650T3 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
| IL131386A0 (en) | Method for the detection and localization of malignant human tumours | |
| EP1458734A4 (de) | Derivate von isoindigo, indigo und indirubin und deren verwendung bei der behandlung von krebs | |
| MY121623A (en) | Methods of preventing breast cancer. | |
| IL136733A0 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| EP1007055A4 (de) | Methode zur verabreichung von amifostin | |
| NZ511280A (en) | Treatment of tumors by administration of growth hormone releasing compounds and their antagonists | |
| IL140029A0 (en) | Radioiodinated phenols for brachytherapy | |
| IL159241A0 (en) | Use of branched-chain fatty acids and derivatives thereof for the treatment of pain | |
| YU77002A (sh) | Postupak i preparat za tretiranje kancera putem davanja hemoterapeutskog agensa koji indukuje apoptozis | |
| GR3031114T3 (en) | Use of a pregnane derivatives for the treatment of tumours. | |
| KR930700163A (ko) | 연조직 종양의 치료 및/또는 진단 방법 | |
| CA2069638A1 (en) | Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands | |
| PL344414A1 (en) | Combination therapy for the treatment of tumors | |
| DE50212918D1 (de) | Polypeptid, dessen konjugat doxorubicin enthält, uetzung | |
| GR3030856T3 (en) | Use of somatostatin analogues for treating melanomas | |
| AU557139B2 (en) | Nitrosourea derivatives | |
| BG106180A (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| RU2004115104A (ru) | Расар-композиции и способы визуализации злокачественных опухолей, а также их терапия | |
| AU3282700A (en) | Solution for injection for the treatment of arthroses | |
| AU4918900A (en) | Interferon-beta use in the treatment of ewing's family of tumors |